## Background: The Pediatric Crohn's Disease Activity Index (PCDAI) has become the standard outcome measure in pediatric Crohn's disease (CD) clinical research. Other versions have been proposed but without systematic evaluation. The aim was to assess validity and responsiveness of the abbreviated
Short pediatric Crohn's disease activity index for quality improvement and observational research
β Scribed by Michael D. Kappelman; Wallace V. Crandall; Richard B. Colletti; Anthony Goudie; Ian H. Leibowitz; Lynn Duffy; David E. Milov; Sandra C. Kim; Bess T. Schoen; Ashish S. Patel; John Grunow; Evette Larry; Gerry Fairbrother; Peter Margolis
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 127 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
β¦ Synopsis
Background: Practical and objective instruments to assess pediatric Crohn's disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohn's Disease Activity Index (PCDAI) and the Abbreviated PCDAI (APC-DAI); and 2) to create a Short PCDAI by retaining and reweighting the most practical and informative components.
Methods: Physicians in the ImproveCareNow Collaborative for pediatric inflammatory bowel disease (IBD) were asked to record components of the PCDAI and assign a Physician Global Assessment (PGA) of disease severity at each patient encounter. We assessed the feasibility of the PCDAI, the APCDAI, and the individual index components by determining the proportion of visits in which data were recorded. We created a short index by retaining and reweighting components of the PCDAI completed in 80% of visits. The feasibility of the Short PCDAI and its ability to discriminate between PGA categories were evaluated using descriptive statistics.
Results:
This study population included 1355 subjects with CD (6373 visits). The PCDAI and APCDAI were complete in 16.7% and 44.1% of visits, respectively. A Short PCDAI, including general well-being, abdominal pain, stools, weight, abdominal exam, and extraintestinal manifestations were completed in 66.5% of visits. The correlation between the Short PCDAI and PGA was similar to that of the PCDAI (r ΒΌ 0.60, P < 0.001 versus 0.61, P < 0.001).
Conclusions:
The Short PCDAI is a practical and valid tool to measure pediatric CD activity. Its use should facilitate quality improvement and observational research.
π SIMILAR VOLUMES
## Background: The aim of this study was to develop a shortened Crohn's Disease Activity Index (CDAI). Methods: A short CDAI was developed retrospectively using patient-level data from four budesonide clinical trials to select variables from the full CDAI which best predicted health-related quali
## Background: Infliximab induces remission and improves the health-related quality of life (hrqol) of patients with refractory or fistulous crohn's disease (cd). however, little information is available as to whether its effect on hrqol is sustained over time. the objective was to measure the hrqo
Background: The use of magnetic resonance imaging (MRI) for assessment of Crohn's disease (CD) is expanding. The aim of this study is to define and provide an external validation of the MRI predictors of active CD, severe CD, and a quantitative Magnetic Resonance Index of Activity (MaRIA). Methods:
Background: According to current guidelines methotrexate (MTX) should be considered as a second-line immunomodulator in patients with chronic active Crohn's disease (CD) if purine analogs are not tolerated or there is a lack of efficacy. However, its therapeutic role remains controversial to the pre